Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GNI Group ( (JP:2160) ) has issued an update.
GNI Group has postponed the disclosure of its full-year 2026 consolidated earnings forecast and related earnings presentation materials, as well as an earnings briefing that had been scheduled for February 24, 2026. The company cites both regulatory constraints linked to its U.S.-listed subsidiary Gyre Therapeutics, whose own results are due in mid-March, and the difficulty of reasonably estimating key variables affecting 2026 performance.
Management says detailed segment and outlook information is tightly connected to Gyre Therapeutics’ performance, and early disclosure in Japan could raise concerns under U.S. fair disclosure rules. In addition, earnings are highly sensitive to the approval timing, launch schedule, and pricing of F351 and to R&D progress at Cullgen, making forecasts currently unreliable and therefore classified as undetermined.
The decision reflects a revised disclosure policy as F351 enters a pivotal phase toward a planned NDA submission in the first half of 2026, with the company emphasizing strict information control aligned with global standards. GNI argues that prioritizing compliance and governance around this first-in-class drug candidate will support long-term shareholder value, and it plans to release materials and forecasts once Gyre’s announcement is complete and reasonable estimates are possible.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange Growth market. Through subsidiaries including U.S.-listed Gyre Therapeutics, Inc. and Cullgen, Inc., it focuses on developing innovative therapies such as F351 for liver fibrosis caused by chronic hepatitis B, targeting global markets for specialty pharmaceuticals.
Average Trading Volume: 1,371,545
Technical Sentiment Signal: Buy
Current Market Cap: Yen143.2B
For a thorough assessment of 2160 stock, go to TipRanks’ Stock Analysis page.